Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Szamarzewskiego 84 St., 60-569 Poznan, Poland.
Department and Division of Physiology, Poznan University of Medical Sciences, Swiecickiego 6 St., 60-781 Poznan, Poland.
Int J Environ Res Public Health. 2020 Mar 4;17(5):1660. doi: 10.3390/ijerph17051660.
Vitamin D fractions can be involved in the pathogenesis of metabolic disorders, but their concentrations are rarely determined. The aim of this study was to evaluate the concentration of vitamin D fractions in obese hypertensive patients and to determine its associations with anthropometric parameters, glucose levels, and lipid profiles. A total of 85 obese hypertensive patients (OBHT) and 40 nonobese nonhypertensive subjects (NOBNHT) underwent biochemical measurements of lipid profiles, glycemia, 25-hydroxyvitamin D (25(OH)D), free vitamin D (free25(OH)D), vitamin D binding protein, albumin levels. Moreover, free25(OH)D and bioavailable25(OH)D (bio25(OH)D) concentrations were calculated. Blood pressure and anthropometric measurements were performed. Differences between groups ( < 0.001) were found for 25(OH)D (OBHT 40.25 ± 18.02 vs. NOBNHT 64.10 ± 22.29 nmol/L), free25(OH)D (9.77 (7.46; 11.49) vs. 13.80 (10.34; 16.82) pmol/L), bioavailable 25(OH)D (3.7 (2.8; 4.4) vs. 5.4 (4.2; 6.7) nmol/L), and calculated free25(OH)D (7.82 (5.54; 11.64) vs. 10.46(8.06;16.28) pmol/L, = 0.002). The OBHT patients showed no relationship between vitamin D fractions concentration and glucose or lipids level, although it was associated with anthropometric parameters. In the NOBNHT group, vitamin D fractions correlated positively with HDL cholesterol and negatively with triglyceridemia and hip circumference. Vitamin D fractions were decreased in obese hypertensive subjects, and were associated with anthropometric parameters, but not with glucose level or lipid profiles; they thus cannot be considered as a predictive marker of metabolic disorders in this group of patients.
维生素 D 分数可能与代谢紊乱的发病机制有关，但它们的浓度很少被确定。本研究旨在评估肥胖高血压患者维生素 D 分数的浓度，并确定其与人体测量参数、血糖水平和血脂谱的关系。共有 85 名肥胖高血压患者（OBHT）和 40 名非肥胖非高血压患者（NOBNHT）进行了血脂谱、血糖、25-羟维生素 D（25(OH)D）、游离维生素 D（free25(OH)D）、维生素 D 结合蛋白和白蛋白水平的生化测量。此外，还计算了游离 25(OH)D（free25(OH)D）和生物可利用 25(OH)D（bio25(OH)D）的浓度。测量了血压和人体测量参数。两组之间存在差异（<0.001），包括 25(OH)D（OBHT 40.25±18.02 vs. NOBNHT 64.10±22.29 nmol/L）、游离 25(OH)D（9.77（7.46；11.49） vs. 13.80（10.34；16.82）pmol/L）、生物可利用 25(OH)D（3.7（2.8；4.4） vs. 5.4（4.2；6.7）nmol/L）和计算出的游离 25(OH)D（7.82（5.54；11.64） vs. 10.46（8.06；16.28）pmol/L，=0.002）。OBHT 患者的维生素 D 分数浓度与血糖或血脂水平之间没有关系，但与人体测量参数有关。在 NOBNHT 组中，维生素 D 分数与高密度脂蛋白胆固醇呈正相关，与三酰甘油和臀围呈负相关。肥胖高血压患者的维生素 D 分数降低，与人体测量参数有关，但与血糖水平或血脂谱无关；因此，它们不能作为该组患者代谢紊乱的预测标志物。
